Literature DB >> 27556741

Association of Lymph Node Status With Survival in Patients After Liver Resection for Hilar Cholangiocarcinoma in an Italian Multicenter Analysis.

Felice Giuliante1, Francesco Ardito1, Alfredo Guglielmi2, Luca Aldrighetti3, Alessandro Ferrero4, Fulvio Calise5, Stefano M Giulini6, Elio Jovine7, Claudio Breccia1, Agostino M De Rose1, Antonio D Pinna8, Gennaro Nuzzo1.   

Abstract

Importance: The prognostic value of lymph node (LN) assessment after liver resection for hilar cholangiocarcinoma (HC) is still controversial, and the number of LNs required to be removed to obtain adequate staging is not well defined.
Objectives: To evaluate the LN status in patients after liver resection for HC and to clarify which prognostic factor (the number of positive LNs or the LN ratio [LNR]) was most accurate for staging and what minimum number of retrieved LNs was required for adequate staging. Design, Setting, and Participants: Retrospective multicenter study of patients who underwent resection for HC between January 1, 1992, and December 31, 2007, at 8 hepatobiliary Italian centers. The last follow-up was assessed in July 2014. Main Outcome and Measures: Differences in overall survival (OS) according to the LN status were analyzed. The OS results were defined as actual because all included patients completed a 5-year follow-up.
Results: One-hundred seventy-five patients with 1133 retrieved LNs were analyzed. The mean (SD) age of the cohort was 63 (10) years, and 42.9% (75 of 175) were female. The median number of LNs examined per patient was 6.5. Forty percent (70 of 175) had LN metastasis. An LNR exceeding 0.20 was associated with significantly lower 5-year OS than an LNR of 0.20 or less (10.6% vs 24.4%; odds ratio, 2.434; 95% CI, 1.020-5.810; P = .04). On multivariable analysis, the LNR was the only independent prognostic factor for OS but was influenced by the total number of retrieved LNs. The LNR was greater than 0.20 in all patients (30 of 30) with 1 to 4 retrieved LNs and in 52.5% (21 of 40) of patients with at least 5 retrieved LNs. Five-year OS in patients with 1 to 5 retrieved LNs was significantly lower than that in those with 6 to 7 retrieved LNs and those with at least 8 retrieved LNs (34.2%, 64.5%, and 62.7%, respectively; P = .047). Five-year OS did not significantly improve when the number of retrieved LNs was greater than 6. These results were confirmed in a receiver operating characteristic curve analysis performed among N0R0 patients, in whom 5 retrieved LNs was the most accurate cutoff to predict 5-year actual OS (area under the curve, 0.624; P = .004). Conclusions and Relevance: An LNR exceeding 0.20 was the only independent prognostic factor for OS in N1 patients after liver resection for HC. However, the LNR was influenced by the total number of retrieved LNs, and removal of more than 5 LNs was the minimum number of LNs required for adequate staging.

Entities:  

Mesh:

Year:  2016        PMID: 27556741     DOI: 10.1001/jamasurg.2016.1769

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  15 in total

1.  Clinical Implications of Biliary Confluence Pattern for Bismuth-Corlette Type IV Hilar Cholangiocarcinoma Applied to Hemihepatectomy.

Authors:  Gu-Wei Ji; Fei-Peng Zhu; Ke Wang; Chen-Yu Jiao; Zi-Cheng Shao; Xiang-Cheng Li
Journal:  J Gastrointest Surg       Date:  2017-02-06       Impact factor: 3.452

2.  Wip1 is associated with tumorigenity and metastasis through MMP-2 in human intrahepatic cholangiocarcinoma.

Authors:  Sulai Liu; Bo Jiang; Hao Li; Zili He; Pin Lv; Chuang Peng; Yonggang Wang; Wei Cheng; Zhengquan Xu; Wei Chen; Zhengkai Liu; Bao Zhang; Shengqian Shen; Shuanglin Xiang
Journal:  Oncotarget       Date:  2017-05-23

3.  Prognostic value of lymphovascular invasion in Bismuth-Corlette type IV hilar cholangiocarcinoma.

Authors:  Bei Li; Xian-Ze Xiong; Yong Zhou; Si-Jia Wu; Zhen You; Jiong Lu; Nan-Sheng Cheng
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

4.  Cholangiocarcinoma: three different entities based on location.

Authors:  Christopher T Aquina; Timothy M Pawlik; Aslam Ejaz
Journal:  Ann Transl Med       Date:  2020-06

Review 5.  The clinicopathological factors associated with prognosis of patients with resectable perihilar cholangiocarcinoma: A systematic review and meta-analysis.

Authors:  Zengwei Tang; Yuan Yang; Zhonghong Zhao; Kongyuan Wei; Wenbo Meng; Xun Li
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

6.  Prognostic Predictability of American Joint Committee on Cancer 8th Staging System for Perihilar Cholangiocarcinoma: Limited Improvement Compared with the 7th Staging System.

Authors:  Jong Woo Lee; Jae Hoon Lee; Yejong Park; Woohyung Lee; Jaewoo Kwon; Ki Byung Song; Dae Wook Hwang; Song Cheol Kim
Journal:  Cancer Res Treat       Date:  2020-03-12       Impact factor: 4.679

7.  Increasing negative lymph node count is independently associated with improved long-term survival in resectable perihilar cholangiocarcinomas.

Authors:  Yunfeng Gao; Dong Xu; Yu-Shen Wu; Duke Chen; Wanchun Xiong
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

8.  iNOS is associated with tumorigenicity as an independent prognosticator in human intrahepatic cholangiocarcinoma.

Authors:  Sulai Liu; Jinqiong Jiang; Linsheng Huang; Yu Jiang; Nanhui Yu; Xiehong Liu; Yuan Lv; Hao Li; Lianhong Zou; Chuang Peng; Xing Yu; Bo Jiang
Journal:  Cancer Manag Res       Date:  2019-08-26       Impact factor: 3.989

Review 9.  The value of lymphadenectomy in surgical resection of perihilar cholangiocarcinoma: a systematic review and meta-analysis.

Authors:  Lei Liang; Chao Li; Ming-Da Wang; Hao Xing; Yong-Kang Diao; Hang-Dong Jia; Wan Yee Lau; Timothy M Pawlik; Cheng-Wu Zhang; Feng Shen; Dong-Sheng Huang; Tian Yang
Journal:  Int J Clin Oncol       Date:  2021-06-23       Impact factor: 3.402

Review 10.  Extended lymphadenectomy in hilar cholangiocarcinoma: What it will bring?

Authors:  Jian Li; Meng-Hao Zhou; Wen-Jie Ma; Fu-Yu Li; Yi-Lei Deng
Journal:  World J Gastroenterol       Date:  2020-06-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.